The U.S. Office of Management and Budget (OMB) has published a new memo that takes more full aim at regulatory activity by executive branch agencies by redefining the activities subject to review by the Office of Information and Regulatory Affairs (OIRA). The new memo says that any rule, which is defined "expansively" to include guidances, must undergo review at OIRA, a requirement that could significantly delay the issuance of guidances by the U.S. FDA.